N/A
N=10
Natural Orifice Transgastric Endoscopic (NOTES) Transgastric Diagnostic Peritoneoscopy With Laparoscopic Assistance
Abdominal Adhesions
Bottom Line
View on ClinicalTrials.gov: NCT00962650 ↗Enrolled (actual)
10
Serious AEs
10.0%
Results posted
Mar 2012
Primary outcome: Primary: Completion of Diagnostic Peritineoscopy — 8 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Transgastric diagnostic peritoneoscopy with laparoscopic assistance (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Ethicon Endo-Surgery
- Primary completion
- Oct 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Completion of Diagnostic Peritineoscopy |
8 | — |
Summary
The study will document being able to successfully perform transgastric diagnostic peritoneoscopy (laparoscopic visualization) using a small collection of study surgical tools.
Eligibility Criteria
Inclusion Criteria
Men and women will be enrolled in this study who:
- Are willing to give consent and comply with evaluation and treatment schedule;
- At least 18 years of age;
- Are a candidate for surgical weight loss intervention (i.e. meet ASMBS and NIH criteria) for an RYGB procedure at the Investigational site;
- Have a history of open abdominal surgery or laparoscopic abdominal surgery;
- ASA Classification I, II, or III (Appendix II); and
- Have a negative serum pregnancy test (for women of childbearing potential).
Exclusion Criteria
Subjects will be excluded from the study for any of the following:
- Use of immunosuppressive medications (within 6 months of surgery; single burst dosages and inhalable steroids are acceptable);
- Acute cholecystitis or acute pancreatitis;
- Evidence of abdominal abscess or mass;
- Diffuse peritonitis;
- Use of anticoagulants or anti-platelet agents (use of daily cardio protective doses of aspirin, up to 81 mg/day, is acceptable and shall not constitute an exclusion criterion) or the presence of coagulopathy;
- Clinical diagnosis of sepsis;
- Co-morbid condition(s) that could limit the subject's ability to participate in the study or to comply with follow-up requirements, or that could impact the scientific integrity of the trial;
- Planned concurrent surgical procedure other than RYGB or adhesiolysis;
- Prior or planned major surgical procedure within 30 days before or after study procedure;
- Participation in any other investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints;
- Previously enrolled in the current series of 4 trials investigating the EES NOTES GEN1 Toolbox; or
- Any condition which precludes compliance with the study (Investigator discretion).
Data sourced from ClinicalTrials.gov (NCT00962650). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.